Comment from Blood Cancer United

Summary: Blood Cancer United opposes the Commissioner’s National Priority Voucher (CNPV) Pilot Program, arguing that it shifts drug approval decisions from independent career experts to political appointees. The organization expresses concern that this process lacks scientific rigor, invites political influence, and may lead to reduced insurance coverage for patients.